M&A / Deals

MSD concludes Terns acquisition to expand CML pipeline

Pharmaceutical Business Review

Following a successful tender offer and subsequent merger, the companies announced the completion of the transaction, making Terns a wholly owned subsidiary of MSD.

Hematology

Read full story

pharminent May 6, 2026 (Last updated: May 6, 2026)

Pharmaceutical Business Review

Following a successful tender offer and subsequent merger, the companies announced the completion of the transaction, making Terns a wholly owned subsidiary of MSD.

Hematology

Read full story

Related Stories

Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout

CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026

GSK bolts on siRNA drug from China’s SiranBio in $1bn deal

You May Have Missed

Novo hikes guidance on Wegovy pill’s fast sales start

Bayer looks to uphold Eylea legacy with $2.45bn Perfuse buyout

FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight

CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026